Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 81
Warning: fopen(upload/ip_log/ip_log_2024-05.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 83
Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 Praziquantel(Distocide®) in treatment of Clonorchis sinensis infection
Praziquantel(Distocide®) in treatment of Clonorchis sinensis infection
Byong-Seol Seo,Soon-Hyung Lee,Jong-Yil Chai and Sung-Tae Hong
Department of Parasitology and Institute of Endemic Diseases, College of Medicine, Seoul National University, Korea.
Abstract
Praziquantel(Distocide®), the Korean product, was tested for its safety and efficacy in treatment of Clonorchis sinensis infection during the period from April to September, 1983 in Korea. A total of 55 egg positive cases were selected and treated with the regimen of 25 mg/kg t.i.d. for 1 day (total 75 mg/kg). The follow-up stool examination was done in 47 cases by cellophane think smear and Stoll's egg counting techniques. The 8 uncured cases were treated again with the same regimen. The laboratory tests for blood picture and liver function were done in 27 cases and compared before and after the treatment.
The results obtained are as follows:
1. After single course treatment, the cure and egg reduction rates were 83.0% and 99.1% respectively. With the second treatment, excellent results of 100% in both rates were obtained.
2. Several kinds of side effects such as dizziness, headache, etc. were complained by 29 cases (61.7%), however, those were so mild and transient that no special treatment was necessary.
3. No significant chang in laboratory findings was recognizable before and after the treatment.
From the above results, it is concluded that Distocide® is as effective and safe as Biltricide® and highly recommendable in treatment of C. sinensis infection.
Tables
Table 1 Cure rate of C. sinensis infection by praziquantel* treatment
Table 2 Distribution of treatment failure cases according to the degree of pre-treatment *E.P.G. value
Table 3 Egg reduction rate of C. sinensis by praziquantel treatment
Table 4 Number of patients who complained side effects following praziquantel treatment
Table 5 Laboratory findings in the patients before and after treatment with praziquantel
References
1.
Ambroise-Thomas P, Goullier A. [Study on the tolerability of high doses of praziquantel in Laotians with parasitic liver infections (authors transl)]. Arzneimittelforschung 1981;31(3a):599–600.
2.
Ambroise-Thomas P, Goullier A, Wegner DG. [Praziquantel in the treatment of Far Eastern hepatic distomiasis caused by Clonorchis sinensis or Opisthorchis viverrini]. Bull Soc Pathol Exot Filiales 1981;74(4):426–433.
3.
Bartsch H, Kuroki T, Malaveille C, Loprieno N, Barale R, Abbondandolo A, Bonatti S, Rainaldi G, Vogel E, Davis A. Absence of mutagenicity of praziquantel, a new, effective, anti-schistosomal drug, in bacteria, yeasts, insects and mammalian cells. Mutat Res 1978;58(23):133–142.
4.
Bunnag D, Harinasuta T. Studies on the chemotherapy of human opisthorchiasis in Thailand: I. Clinical trial of praziquantel. Southeast Asian J Trop Med Public Health 1980;11(4):528–531.
5.
Bunnag D, Harinasuta T. Studies on the chemotherapy of human opisthorchiasis: III. Minimum effective dose of praziquantel. Southeast Asian J Trop Med Public Health 1981;12(3):413–417.
6.
Chen CY, Hsieh WC. Clinical investigation of praziquantel in the treatment of clonorchiasis sinensis. Taiwan Yi Xue Hui Za Zhi 1982;81(11):1434–1442.
7.
Davis A, Biles JE, Ulrich AM, Dixon H. Tolerance and efficacy of praziquantel in phase II A and II B therapeutic trials in Zambian patients. Arzneimittelforschung 1981;31(3a):568–574.
8.
Gönnert R, Andrews P. Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 1977;52(2):129–150.
9.
Kim MS, et al. Korea Univ Med J 1982;19:107–121.
10.
Obermeier J, Frohberg H. Mutagenicity studies with praziquantel, a new anthelmintic drug: tissue-, host-, and urine-mediated mutagenicity assays. Arch Toxicol 1977;38(3):149–161.
11.
Rim HJ, et al. Korea Univ Med J 1980;17:113–128.
12.
Rim HJ, Chang YS, Lee JS, Joo KH, Suh WH, Tsuji M. Clinical Evaluation Of Praziquantel(Embay 8440; Biltricide(R)) In The Treatment Of Paragonimus Westermani. Korean J Parasitol 1981;19(1):27–37.
13.
Rim HJ, Chu DS, Lee JS, Joo KH, Won CY. [Anthelmintic Effects Of Various Drugs Against Metagonimiasis]. Korean J Parasitol 1978;16(2):117–122.
14.
Rim HJ, Lyu KS, Lee JS, Joo KH. Clinical evaluation of the therapeutic efficacy of praziquantel (Embay 8440) against Clonorchis sinensis infection in man. Ann Trop Med Parasitol 1981;75(1):27–33.
15.
Rim HJ, Lee YM, Lee JS, Joo KH. Therapeutic field trial with praziquantel (Biltricide(R)) in a rural population infected with Clonorchis sinensis. Korean J Parasitol 1982;20(1):1–8.
16.
Rim HJ, et al. Korea Univ Med J 1979;16:459–470.
17.
Seo BS, Lee SH, Cho SY, Chai JY, Hong ST, Han IS, Sohn JS, Cho BH, Ahn SR, Lee SK, Chung SC, Kang KS, Shim HS, Hwang IS. An Epidemiologic Study On Clonorchiasis And Metagonimiasis In Riverside Areas In Korea. Korean J Parasitol 1981;19(2):137–150.
18.
Soh CT, et al. Yonsei Reports on Trop Med 1981;12:22–32.
19.
Soh CT, et al. Yonsei Reports on Trop Med 1980;11:51–57.
20.
Thomas H, Gönnert R. The efficacy of praziquantel against cestodes in animals. Z Parasitenkd 1977;52(2):117–127.
PDF Links
Full text via DOI
Download Citation 
